Routine articles of association update with no trading signal. Monitor for future capital increases under the authorized shelf capacity, which could create modest dilution if exercised.
Price Chart
Executive Summary
Genmab filed its updated Articles of Association as a 6-K, reflecting routine governance updates including share capital details, authorized capital increases, employee warrant programs, and board indemnification provisions. No financial results, material transactions, or operational catalysts were disclosed.
Key Facts
- Share capital is DKK 62,405,855 divided into shares of DKK 1 each.
- Board authorized through March 12, 2029 to increase capital by up to DKK 6,600,000 without pre-emption rights and up to DKK 6,600,000 with pre-emption rights.
- Board authorized through March 12, 2029 to issue convertible debt instruments up to nominally DKK 3,000,000 new shares.
- Multiple employee warrant programs detailed, with aggregate potential dilution capped at DKK 750,000 nominal per authorization tranche.
- Board indemnification scheme established through March 12, 2029, excluding fraud, criminal offenses, willful misconduct, or gross negligence.
Financial Impact
No financial impact, routine governance filing with no revenue, earnings, or material transaction data.
Risk Factors
- Potential future dilution from authorized but unexercised capital increases and warrant programs.
- No material business or financial updates in this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000127 |
| Document: gmab_20260929x6k.htm | 0001434265-26-000127 |
| Document: 0001434265-26-000127-index-headers.html | 0001434265-26-000127 |
| Document: 0001434265-26-000127-index.html | 0001434265-26-000127 |
| Document: 0001434265-26-000127.txt | 0001434265-26-000127 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 6-K | $57.29 $56.49 | ▼ −1.40% | ▼ −1.01% | $56.49 (−1.40%) |
Oct 23, 2026 6d ago | 6-K | $43.79 $44.69 | ▲ +2.04% | ▲ +1.33% | $56.49 (+29.00%) |
Oct 13, 2026 16d ago | 6-K | $36.57 $36.89 | ▲ +0.88% | ▲ +1.96% | $56.49 (+54.47%) |
Oct 7, 2026 22d ago | 6-K | $36.65 $36.05 | ▼ −1.64% | ▼ −1.21% | $56.49 (+54.13%) |
Oct 5, 2026 24d ago | SC 13G | $37.80 $36.65 | ▼ −3.04% | ▼ −2.80% | $56.49 (+49.44%) |
Oct 5, 2026 24d ago | 6-K | $38.48 $37.80 | ▼ −1.77% | ▼ −2.32% | $56.49 (+46.80%) |
Oct 2, 2026 27d ago | 6-K | $34.75 $38.48 | ▲ +10.73% | ▲ +10.06% | $56.49 (+62.56%) |
Sep 29, 2026 4w ago | 6-K | $35.57 $35.68 | ▲ +0.30% | ▲ +0.50% | $56.49 (+58.81%) |
Sep 24, 2026 5w ago | 6-K | $34.83 $35.32 | ▲ +1.41% | ▲ +0.86% | $56.49 (+62.19%) |
Sep 8, 2026 7w ago | 6-K | $33.53 $33.04 | ▼ −1.46% | ▼ −1.00% | $56.49 (+68.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers